Mednow Acquires the License and Exclusive Canadian Distribution Rights for Genetic Testing Technology from TruDiagnostic™
Mednow has entered a two-year investment agreement to acquire the License and Exclusive Distribution Rights of TruDiagnostic™ in Canada for a cash payment of US$150,000. This collaboration enhances Mednow's digital health offerings, allowing for epigenetic testing that quantifies aging through methylation biomarkers. The TruAge Complete Collection can provide insights into biological age, immune age, and telomere length. Mednow aims to offer a holistic healthcare ecosystem, expecting to integrate these services into its platform in Q1 2022.
- Acquisition of exclusive distribution rights for TruDiagnostic™ enhances Mednow's digital health services.
- Potential to expand Mednow's market offerings, focusing on preventive healthcare and aging analysis.
- Expected integration of TruDiagnostic™ services into Mednow's platform enhances user experience.
- None.
- TruDiagnostic™ TruAge Complete Collection is a comprehensive way for a patient to analyze methylation biomarkers to quantify the process of aging
-
Mednow acquires the License and Exclusive Distribution Rights of TruDiagnostic™ for a two-year term for a cash payment ofUS $150,000 - Expands Mednow’s holistic healthcare offerings on its digital platform
Mednow’s strategy is to develop a digital interdisciplinary model of care. Anchored in pharmacy and supported by telemedicine and complementary health care services, having the exclusive distribution rights of TruDiagnostic™ in
TruDiagnostic™ TruAge Complete Collection is a comprehensive way for a patient to analyze methylation biomarkers to quantify the process of aging. Aging is the number one risk factor for most chronic diseases and death. By quantifying this process, individuals can potentially predict future diseases and treat aging as a primary objective factor. The TruAge Complete collection allows everyone to look at their aging process by providing them their biological age, their immune age, and telomere length. It also includes the Dunedin Pace of Aging analysis, developed by
In the first quarter of 2022, it is anticipated that Mednow’s patients will be able to: order the test on its website, have their blood specimen taken, and shipped back to the lab for testing and diagnosis. This agreement between
“We continually endeavor unique pharmacy and healthcare solutions as part of our patient-centric approach. We recognize Canadians are expanding their initiatives when it comes to preventative medicine. By acquiring the exclusive distribution rights to TruDiagnostic™ we can deliver a solution for epigenetic testing for patients to live their healthiest life,” said
About
To learn more, follow
About TruDiagnostic™
TruDiagnostic™ is a
Neither
Cautionary Note Regarding Forward-Looking Statements:
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information, including statements relating to: the Company’s intention to continue to build a holistic approach to patient care, the expectation that the number of diseases attributable to people would be reduced if everyone were able to reduce their epigenetic biological age to 7 years younger than their chronological age and the expectation that the Company’s patients will be able to order the test on its website, have their blood specimen taken, and shipped back to the lab for epigenetic testing and analysis in the first quarter of 2022. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Company will to continue to build a holistic approach to patient care, that the number of diseases attributable to people would be reduced if everyone were able to reduce their epigenetic biological age to 7 years younger than their chronological age and that the Company’s patients will be able to order the test on its website, have their blood specimen taken, and shipped back to the lab for testing and diagnosis in the first quarter of 2022. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, that the Company will not continue to build a holistic approach to patient care as anticipated by management, that the number of diseases attributable to people would not be reduced if everyone were able to reduce their epigenetic biological age to 7 years younger than their chronological age and that the Company’s patients will not be able to order the test on its website, have their blood specimen taken, and shipped back to the lab for testing and diagnosis in the first quarter of 2022 or at all, and other risk factors set out in the Company’s final long form prospectus dated
View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005539/en/
Investor Relations Contact:
ir@mednow.ca
1.855.686.6300
Media Contact:
Kieran.lawler@loderockadvisors.com
416.303.0799
Source:
FAQ
What are the details of Mednow's acquisition of TruDiagnostic™?
How will Mednow's acquisition of TruDiagnostic™ impact its services?
When will Mednow's TruDiagnostic™ services be available to patients?
What is the significance of the TruAge Complete Collection?